Table 2.
Baseline characteristics of patients treated with alectinib (n = 52)
| Patient characteristic | Median Cmin < 435 ng/mL (n = 19) | Median Cmin ≥ 435 ng/mL (n = 33) | All patients (n = 52) |
|---|---|---|---|
| Gender, female | 8 (42%) | 20 (61%) | 28 (54%) |
| Age (years) | 54 (21–70) | 60 (34–88) | 57 (21–88) |
| Weight (kg) | 76 (54–123) | 79 (49–117) | 78 (49–123) |
| Tumor stage | |||
| IIIA | 0 | 1 (3%) | 1 (2%) |
| IIIB | 0 | 2 (6%) | 2 (4%) |
| IV | 19 (100%) | 30 (91%) | 49 (94%) |
| Brain metastases, yes | 10 (53%) | 10 (30%) | 20 (39%) |
| Previous lines of systemic therapy | |||
| 0 | 3 (16%) | 13 (39%) | 16 (31%) |
| 1 | 8 (42%) | 12 (36%) | 20 (39%) |
| ≥ 2 | 8 (42%) | 8 (24%) | 16 (31%) |
| Prior treatment with ALK inhibitor(s), yes | 16 (84%) | 19 (58%) | 35 (67%) |
| Alectinib dose a | |||
| 600 mg b.i.d. | 16 (84%) | 15 (45%) | 31 (60%) |
| 450 mg b.i.d. | 1 (5%) | 8 (24%) | 9 (17%) |
| 300 mg b.i.d. | 2 (11%) | 10 (30%) | 12 (23%) |
| WHO performance status | |||
| 0 | 11 (58%) | 6 (18%) | 17 (33%) |
| 1 | 8 (42%) | 21 (64%) | 29 (56%) |
| ≥ 2 | 0 | 4 (12%) | 4 (8%) |
| Missing | 0 | 2 (6%) | 2 (4%) |
Data are expressed as no. (%) or median (range), as appropriate.
ALK, anaplastic lymphoma kinase; b.i.d., twice daily; Cmin, minimum plasma concentration; WHO, World Health Organization.
a
Lowest dose per patient.